Wellcome Trust grant to investigate degenerative brain diseases known as `tauopathies`April 17, 2002Dr Julian Thorpe, head of the Electron Microscopy Lab at the University of Sussex, will be working towards a better understanding of degenerative brain diseases thanks to a £247,000 grant from the Wellcome Trust. He is taking a very close look at a possible contributory cause of nerve cell death in a group of conditions related to Alzheimer's disease. "Alzheimer's disease is characterised by 'plaques' which are outside the brain cells and also 'tangles' which are inside the cells," says Julian. "In the group of diseases known as 'tauopathies' there are no plaques but they do have the tangles." The taupathies include Down`s Syndrome, progressive supranuclear palsy (which Dudley Moore died from recently), Pick`s disease, corticobasal degeneration, and frontotemporal dementia. In Alzheimer's disease, a protein known as Pin1 interacts with the 'tangles', which consist mainly of 'tau' protein. These tangles are damaged remnants of the cell's supporting 'cytoskeleton' which correlate with the impaired nerve function that leads to dementia. "Pin1 protein is normally predominantly in the nucleus of a cell where it helps to regulate cell division," says Dr Thorpe. "In Alzheimer's disease it has been shown that Pin1 comes out of the nucleus to bind with the tau protein in the tangles, but it seems there isn't enough Pin1 in the cell to cope with all the tau." As Pin1 acts as a kind of housekeeper protein, helping other proteins to carry out their normal functions, this shortage of Pin1 may be what leads to the death of brain cells. "It seems this depletion of Pin1 in the nucleus contributes to the death of the cell and we're going to use electron microscopy and biochemical methods to investigate," says Dr Thorpe. "Our hypothesis is that the Pin1 protein is involved in these diseases as it is with Alzheimer's disease." Julian will be using a transmission electron microscope (TEM) to study human post-mortem brain samples. The other members of the team are Reader in Biochemistry John Kay, Research Fellow Simon Morley and Research Fellow Stuart Rulten. Sussex, University of |
|||||||||||||||||||||
| Related Alzheimer Disease Current Events and Alzheimer Disease News Articles Delirium in hospitalized adults: Situation critical, no relief available Every year as many as seven million adults in the United States experience delirium during hospitalization. New data demonstrate potential for early detection of Alzheimer's disease Data published in the June issue of the Journal of Alzheimer's Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer's disease. Another McGill/JGH breakthrough opens door to early Alzheimer's diagnosis A new diagnostic technique which may greatly simplify the detection of Alzheimer's disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital (JGH). Measuring brain atrophy in patients with mild cognitive impairment Scientists at the University of California, San Diego School of Medicine have shown that a fully automated procedure called Volumetric MRI - which measures the "memory centers" of the brain and compares them to expected size - is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease. Commonly used medications may produce cognitive impairment in older adults Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults. Commonly used ulcer drugs may offer treatment potential in Alzheimer's disease In a new study, published in the May issue of Elsevier's Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug. New test for mysterious metabolic diseases developed at Stanford/Packard Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism. Recalibrating 'fight or flight' A Canadian/U.S. research team has reported a novel approach to stimulating recovery from chronic stress disorders. Details of the therapeutic model, which exploits the natural dynamics of the body's "fight or flight" system, are published January 23 in the open-access journal PLoS Computational Biology Vitamin B does not slow cognitive decline in Alzheimer's A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease. Protecting patient privacy the new fashioned way Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act. More Alzheimer Disease Current Events and Alzheimer Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||